Reema R Mody
Overview
Explore the profile of Reema R Mody including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
391
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mody R, Meyer K, Ward J, ODay K
Diabetes Ther
. 2023 Sep;
14(12):2045-2055.
PMID: 37770706
Introduction: Achieving glycemic control can help reduce complications of type 2 diabetes (T2D). This study compared the pharmacy cost per responder and number needed to treat (NNT) of tirzepatide 5 ...
2.
Olar A, Goodman L, Wani K, Boehling N, Sharma D, Mody R, et al.
Oncotarget
. 2018 Apr;
9(22):16087-16098.
PMID: 29662628
Background: Meningioma is the most common primary brain tumor and has a variable risk of local recurrence. While World Health Organization (WHO) grade generally correlates with recurrence, there is substantial...
3.
Chang W, Pope W, Harris R, Hardy A, Leu K, Mody R, et al.
Tomography
. 2016 Jan;
1(1):37-43.
PMID: 26740971
The standard of care for newly diagnosed glioblastoma (GBM) is surgery, then radiotherapy (RT) with concurrent temozolomide (TMZ), followed by adjuvant TMZ. We hypothesized patients with low diffusivity measured using...
4.
Gupta S, Patel H, Scopel J, Mody R
J Opioid Manag
. 2015 Aug;
11(4):325-38.
PMID: 26312960
Objective: The authors sought to characterize health-related quality of life (HRQoL), medication adherence, productivity losses, and treatment satisfaction associated with modifications to opioid therapy due to opioid-induced constipation (OIC). Design:...
5.
Li S, Chowdhury R, Liu F, Chou A, Li T, Mody R, et al.
Clin Cancer Res
. 2014 Sep;
20(22):5808-22.
PMID: 25224277
Purpose: IDH1/2-mutant gliomas harbor a distinct glioma-CpG island methylation phenotype (G-CIMP) that may promote the initiation and progression of secondary pathway gliomas by silencing tumor-suppressive genes. The potential role of...
6.
Piccioni D, Selfridge J, Mody R, Chowdhury R, Li S, Lalezari S, et al.
Neuro Oncol
. 2014 Mar;
16(6):815-22.
PMID: 24627236
Background: The optimal timing to initiate bevacizumab (BV) therapy for recurrent glioblastoma (GBM) is currently unclear. To address this issue, we examined progression-free survival (PFS) and survival time (ST) in...
7.
Chou A, Chowdhury R, Li S, Chen W, Kim A, Piccioni D, et al.
J Natl Cancer Inst
. 2012 Sep;
104(19):1458-69.
PMID: 22945948
Background: Mutations in isocitrate dehydrogenase 1 (IDH1) and associated CpG island hypermethylation represent early events in the development of low-grade gliomas and secondary glioblastomas. To identify candidate tumor suppressor genes...
8.
Kleinman L, Nelson S, Kothari-Talwar S, Roberts L, Orenstein S, Mody R, et al.
J Pediatr Gastroenterol Nutr
. 2011 Apr;
52(5):514-22.
PMID: 21464757
Objectives: The Pediatric Gastroesophageal Reflux Disease Symptom and Quality of Life Questionnaire (PGSQ) represents 2 related age-stratified tools developed to assess pediatric gastroesophageal reflux disease (GERD). These include the PGSQ-Cp...
9.
Chey W, Mody R, Izat E
Dig Dis Sci
. 2010 Apr;
55(12):3415-22.
PMID: 20397047
Background: Few studies have explored the satisfaction with proton pump inhibitors (PPIs) for gastroesophageal reflux disease (GERD). Aim: The aim of this study was to assess patient and physician satisfaction...
10.
Chey W, Mody R, Wu E, Chen L, Kothari S, Persson B, et al.
Curr Med Res Opin
. 2009 Jun;
25(8):1869-78.
PMID: 19530980
Background: Proton pump inhibitors (PPIs) are the most commonly used pharmacological treatment for gastroesophageal reflux disease (GERD). Objective: To examine the utilization patterns of PPIs and other GERD-related medications, satisfaction...